Company
United StatesPublic company, NASDAQ: RGNXREGENXBIO Inc (NASDAQ: RGNX), Rockville, MD – FDA Inspections
Inspection records and compliance data for REGENXBIO Inc in Rockville, Maryland. 2 FDA inspections on record, last inspected August 04, 2025. Publicly traded as NASDAQ: RGNX.
Company Profile
This profile covers REGENXBIO Inc based in Rockville, Maryland, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 1
- Unclassified
- 1
- Form 483s
- 0
- Warning letters
- 0
First inspected July 31, 2025. Last inspected August 4, 2025.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| August 4, 2025 | Not classified | Biologics | 1298212 |
| July 31, 2025 | NAI | Biologics · Bioresearch Monitoring | 1277369 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
REGENXBIO Inc
Stock ticker
RGNX
Exchange
NASDAQ
Share price
$8.03
Market cap
$531.0M
Price as of
November 13, 2026
FEI Number
3012957259
Address
9804 Medical Center Dr, Rockville, Maryland 20850, United States
Country
United States
ID: 2ce07f8f-c537-4340-96f8-7a3b2e519f31